Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

282 trials

NCT06664411
Recruiting
Pola-ZR2P in Previously Untreated DLBCL
Phase 2 · China · 1 site
Registry update: 19 Aug 2025
NCT06550141
Recruiting
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Phase 2 · United States · 2 sites
Registry update: 6 Oct 2026
NCT06554600
Recruiting
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2 · China · 1 site
Registry update: 15 Aug 2024
NCT06503263
Recruiting
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Phase 2 · China · 1 site
Registry update: 19 Sept 2024
NCT06891157
Recruiting
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Phase 2 · China · 1 site
Registry update: 24 Mar 2025
NCT06822829
Recruiting
Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma
Not applicable · Italy · 1 site
Registry update: 5 May 2026
NCT06395103
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Phase 1/2 · Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Germany, Denmark, Spain, France, United Kingdom, Greece, Hungary, Israel, Italy, South Korea, Netherlands, Sweden, Slovakia, Taiwan, United States · 72 sites
Registry update: 30 Oct 2026
NCT06220032
Recruiting
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Phase 3 · Netherlands · 25 sites
Registry update: 23 Sept 2026
NCT06517511
Recruiting
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
Phase 2 · China · 2 sites
Registry update: 12 Feb 2026
NCT06522555
Recruiting
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
Phase 3 · China · 1 site
Registry update: 5 Aug 2024
NCT06755775
Recruiting
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
Not applicable · China · 1 site
Registry update: 1 Jan 2025
NCT06517004
Recruiting
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase 1 · China · 1 site
Registry update: 24 Jul 2024
NCT05952024
Recruiting
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Phase 2 · Brazil, South Korea, Puerto Rico, Taiwan, United States · 43 sites
Registry update: 30 Oct 2026
NCT06534762
Recruiting
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Phase 2 · China · 1 site
Registry update: 2 Aug 2024
NCT06486051
Recruiting
A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
Phase 2 · New Zealand · 3 sites
Registry update: 7 Aug 2026
NCT06213636
Recruiting
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Phase 1/2 · China · 1 site
Registry update: 6 Aug 2025
NCT06796517
Recruiting
Immunotherapy in Lymphoma
Not applicable · South Korea · 2 sites
Registry update: 28 Jan 2025
NCT06464861
Recruiting
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Phase 1 · China · 1 site
Registry update: 7 Feb 2025
NCT06526065
Recruiting
Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
Not applicable · Germany · 1 site
Registry update: 29 Jul 2024
NCT06500273
Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Phase 2 · Australia, Canada, South Korea, United States · 86 sites
Registry update: 30 Oct 2026

Ordered by registry start date. Freshness and sponsorship never change the order.